Liver capsule: Age‐influenced hepatic immune priming determines HBV infection fate: Implications from mouse to man

Publicover, Jean; Jespersen, Jillian M.; Johnson, A. J.; Nishimura, Stephen L.; Goodsell, Amanda; Wakil, Adil E.; Rosenthal, Philip; Pai, Eric; Avanesyan, Lia; Cooper, Stewart; Baron, Jody L.

doi:10.1002/hep.28284

Cited by 3 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The age range of enrolled subjects may be one of the reasons for the consistency. The fate of HBV infection could be determined by age‐influenced hepatic immune priming 18 . Patients who were included in our study were aged 13–82‐years old, while the individuals in the previous epidemiological investigation were 1–59 years old 6 .…”

Section: Discussionmentioning

confidence: 99%

“…The fate of HBV infection could be determined by age-influenced hepatic immune priming. 18 Patients who were included in our study were aged 13-82-years old, while the individuals in the previous epidemiological investigation were 1-59 years old. 6 We observed that the prevalence of anti-HBc increased with age, which is consistent with several epidemiological studies in the general people in China.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Significance of anti‐HBc serological status in primary immune thrombocytopenia

Wang

et al. 2021

Br J Haematol

View full text Add to dashboard Cite

The association of previous hepatitis B virus (HBV) exposure [hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (anti-HBc/HBcAb) positive] with disease severity and decision on treatment option in primary immune thrombocytopenia (ITP) patients remains unclear. Data from 725 patients diagnosed with ITP were analyzed to elucidate the association between anti-HBc serological status and disease severity. Data from a published prospective study [high-dose dexamethasone (HD-DXM), HD-DXM plus recombinant human thrombopoietin, NCT01734044] and two retrospective studies (standard-dose and low-dose rituximab) were rearranged to evaluate the impact of anti-HBc serological status on the response and outcome to ITP-specific treatments and the risk of HBV reactivation related to these treatments. The prevalence of HBsAg À HBcAb + and HBsAg À HBcAb À in ITP patients was 51Á03% and 48Á97% respectively. Compared to the HBsAg À HBcAb À group, patients in the HBsAg À HBcAb + group had lower platelet count, higher bleeding score, and longer hospitalization (P = 0Á002, 0Á033, and 0Á008 respectively). Moreover, the initial complete response rate of HBsAg À HBcAb + patients was lower than that of HBsAg À HBcAb À patients (45Á2% vs 59Á8%, P = 0Á027). In conclusion, previous HBV exposure was correlated with disease severity and hospitalization in ITP patients. Anti-HBc positivity may be considered as a predictor for poor response to ITP-specific treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Significance of anti‐HBc serological status in primary immune thrombocytopenia

Wang

et al. 2021

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…The young mice developed strikingly weak HBV-dependent inflammatory responses compared with adult mouse recipients. Mechanistically, these studies found that higher HBV-dependent IL-21 production, lymphoid organization facilitated by hepatic macrophages, and immune priming in adult mouse livers may play pivotal roles in determining age-dependent immune response potency upon HBV infection [ 118 , 119 , 120 ].…”

Section: Non-infection Murine Modelsmentioning

confidence: 99%

Animal Models of Hepatitis B Virus Infection–Success, Challenges, and Future Directions

Liu

Maya

Ploß

2021

Viruses

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection affects more than 250 million people worldwide, which greatly increases the risk for terminal liver diseases, such as liver cirrhosis and hepatocellular carcinoma (HCC). Even though current approved antiviral therapies, including pegylated type I interferon (IFN) and nucleos(t)ide analogs, can effectively suppress viremia, HBV infection is rarely cured. Since HBV exhibits a narrow species tropism and robustly infects only humans and higher primates, progress in HBV research and preclinical testing of antiviral drugs has been hampered by the scarcity of suitable animal models. Fortunately, a series of surrogate animal models have been developed for the study of HBV. An increased understanding of the barriers towards interspecies transmission has aided in the development of human chimeric mice and has greatly paved the way for HBV research in vivo, and for evaluating potential therapies of chronic hepatitis B. In this review, we summarize the currently available animal models for research of HBV and HBV-related hepadnaviruses, and we discuss challenges and future directions for improvement.

show abstract

“…1 It is widely accepted that the virus-host interaction, which is affected by age, transmission route, immune status and other factors, determines the outcome of infection. 2,3 Both adaptive and innate immunity are involved in anti-HBV immune response. On one hand, antigen-presenting cells (APCs), including macrophages and dendritic cells (DCs), initialize the virus-specific adaptive immunity characterized by activation of T helper lymphocytes and secretion of various cytokines, which then mobilize the cytotoxic T lymphocyte (CTL) to kill the HBV-infected cells.…”

Section: Introductionmentioning

confidence: 99%

“… 1 It is widely accepted that the virus-host interaction, which is affected by age, transmission route, immune status and other factors, determines the outcome of infection. 2 , 3 …”

Section: Introductionmentioning

confidence: 99%

Macrophage Phenotypes and Hepatitis B Virus Infection

Li¹,

Li²,

Duan³

et al. 2020

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Globally, hepatitis B virus (HBV) infection and its related liver diseases account for 780,000 deaths every year. Outcomes of HBV infection depend on the interaction between the virus and host immune system. It is becoming increasingly apparent that Kupffer cells (KCs), the largest population of resident and monocyte-derived macrophages in the liver, contribute to HBV infection in various aspects. These cells play an important role not only in the anti-HBV immunity including virus recognition, cytokine production to directly inhibit viral replication and recruitment and activation of other immune cells involved in virus clearance but also in HBV outcome and progression, such as persistent infection and development of end-stage liver diseases. Since liver macrophages play multiple roles in HBV infection, they are directly targeted by HBV to benefit its life cycle. In the present review, we briefly outline the current advances of research of macrophages, especially the studies of their phenotypes, in chronic HBV infection.

show abstract

Liver capsule: Age‐influenced hepatic immune priming determines HBV infection fate: Implications from mouse to man

Abstract: Abbreviations CXCL13chemokine (C-X-C motif) ligand 13

Cited by 3 publications

References 2 publications

Significance of anti‐HBc serological status in primary immune thrombocytopenia

Significance of anti‐HBc serological status in primary immune thrombocytopenia

Animal Models of Hepatitis B Virus Infection–Success, Challenges, and Future Directions

Macrophage Phenotypes and Hepatitis B Virus Infection

Contact Info

Product

Resources

About